Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,477 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Insulin Dependent Diabetes Mellitus 1 Clear all
Completed Phase 4 Interventional

A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes

NCT01718093
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Sitagliptin, Metformin, Sitagliptin + Metformin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
13 Years to 18 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Oct 15, 2026, 4:23 PM EDT
Completed Not applicable Interventional Results available

Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia

NCT01621776
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Apidra, Humalog, Novolog
Drug
Lead sponsor
University of Florida
Other
Eligibility
9 Years to 14 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
DeLeon Springs, Florida
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 15, 2026, 4:23 PM EDT
Withdrawn Phase 2 Interventional

Effect of GABA Supplementation in the Progression of Type 1 Diabetes in Children

NCT01561508
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
gamma-amino-butyric acid, Xylitol
Drug · Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
8 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 24, 2012 · Synced Oct 15, 2026, 4:23 PM EDT
Completed Phase 3 Interventional Results available

Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use

NCT01109316
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin lispro 2 day reservoir in-use, Insulin lispro 6 day reservoir in-use, Insulin aspart 6 day reservoir in-use
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
13 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
11
States / cities
Concord, California • Aurora, Colorado • Hollywood, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 15, 2026, 4:23 PM EDT
Completed Not applicable Interventional

InsuLearn Feasibility With Type 1 Diabetes Patients Under MDI Therapy

NCT06411548
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
InsuLearn
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 15, 2026, 4:23 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone

NCT02531035
View directory record Official record
Conditions
Type 1 Diabetes Mellitus (T1DM), High Level of Sugar (Glucose) in the Blood
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
33
States / cities
Concord, California • Escondido, California • La Jolla, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 15, 2026, 4:23 PM EDT
Active, not recruiting Not applicable Interventional

A Randomized Parallel Clinical Trial of AIDANET, an Automated Insulin Delivery Algorithm, in Fully Closed-Loop Vs Hybrid Closed-Loop Mode In Adults With Type 1 Diabetes (AIDANET At Home)

NCT07039617
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
AIDANET + FCL, AIDANET + HCL, AIDANET in FCL-HCL-mixed mode, Automated Insulin Delivery (AID) (usual care)
Device · Other
Lead sponsor
Sue Brown
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 15, 2026, 4:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetic Influence on Susceptibility to Type 1 Diabetes Mellitus

NCT00001985
View directory record Official record
Conditions
Diabetes Mellitus, Healthy
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2008 · Synced Oct 15, 2026, 4:23 PM EDT
Completed Early Phase 1 Interventional

Targeting Beta Cell Dysfunction With Verapamil in Longstanding T1D

NCT05847413
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Verapamil
Drug
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 15, 2026, 4:23 PM EDT
Completed Phase 1 Interventional

A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus

NCT05887999
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
LY3532226, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 15, 2026, 4:23 PM EDT
Terminated Not applicable Interventional

Native American Diabetes Project

NCT05088616
View directory record Official record
Conditions
Diabetes, Diabete Type 2, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetes Type 1, Diabetes Mellitus
Interventions
Virtual Diabetes Wellness Classes and Medically Tailored Meals
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 15, 2026, 4:23 PM EDT
Active, not recruiting Not applicable Interventional

Community Health Workers in Pediatric Patients With Newly Diagnosed Type 1 Diabetes

NCT04238949
View directory record Official record
Conditions
Type 1 Diabetes, Diabetes Mellitus, Psychosocial Problem, Compliance, Patient, Health Behavior
Interventions
Community Health Worker added to diabetes team
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 15, 2026, 4:23 PM EDT
Completed Phase 4 Interventional

Evaluation of the Safety Use of the InsuPatch Device in Daily Life Conditions

NCT01283425
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
InsuPatch
Device
Lead sponsor
Insuline Medical Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Oct 15, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Results available

Clinical Trial of Zocor (Simvastatin) and Vytorin (Ezetimibe/Simvastatin) in Adolescents With Type 1 Diabetes

NCT00477204
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Dyslipidemia
Interventions
Simvastatin, Ezetimibe/Simvastatin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 15, 2026, 4:23 PM EDT
Completed Not applicable Interventional Results available

Effect of Methyldopa on MHC Class II Antigen Presentation in Type 1 Diabetes

NCT01883804
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Methyldopa
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 46 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 15, 2026, 4:23 PM EDT
Completed Phase 3 Interventional Results available

Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine

NCT03874715
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin Aspart SAR341402, Insulin Aspart, Insulin glargine U100
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
33
States / cities
Concord, California • Temecula, California • Ventura, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 15, 2026, 4:23 PM EDT
Completed Phase 3 Interventional

Six Month Clinical Trial Assessing Efficacy and Safety of Inhaled Insulin in Type 1 Diabetes

NCT00424333
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Inhaled human insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 65 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
30
States / cities
Duarte, California • Long Beach, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2007 · Synced Oct 15, 2026, 4:23 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)

NCT03608163
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness
Interventions
Naloxone, Diazoxide, Placebo (for Naloxone), Placebo (for Diazoxide)
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years to 55 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 15, 2026, 4:23 PM EDT
Completed Phase 3 Interventional Results available

Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes

NCT02268214
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Dapagliflozin, Placebo for dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
833 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
36
States / cities
Little Rock, Arkansas • Encino, California • La Mesa, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 15, 2026, 4:23 PM EDT
Completed Not applicable Interventional Results available

Behavioral Approaches to Reducing Diabetes Distress and Improving Glycemic Control

NCT04016558
View directory record Official record
Conditions
Type 1 Diabetes, Diabetes Distress
Interventions
StreamLine, TunedIn, FixIt
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
19 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 15, 2026, 4:23 PM EDT
Completed Early Phase 1 Interventional

Preventing Hypoglycemia During Exercise With Proactive Snacking on Closed Loop

NCT02135068
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Medtronic MiniMed Closed Loop (CL) System, Snacking
Device · Other
Lead sponsor
Yale University
Other
Eligibility
13 Years to 44 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 15, 2026, 4:23 PM EDT
Completed Early Phase 1 Interventional Results available

Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes

NCT01856790
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
ePID closed loop system, liraglutide
Device · Drug
Lead sponsor
Jennifer Sherr
Other
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Oct 15, 2026, 4:23 PM EDT
Completed Not applicable Interventional

Full Day and Night Closed-Loop With DiAs Platform

NCT02147860
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Diabetes Assistant (DiAs) with USS Virginia, Sensor Augmented Pump Therapy
Device · Other
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 35 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Stanford, California • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 15, 2026, 4:23 PM EDT
Completed Early Phase 1 Interventional

Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D

NCT03632759
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Liraglutide, Golimumab
Drug
Lead sponsor
Carla Greenbaum, MD
Other
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Idaho Falls, Idaho • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 15, 2026, 4:23 PM EDT